Handok Pharmaceuticals’ CEO and Chairman Young-Jin Kim and the President of the Gwangju Institute of Science and Technology, Jung-Ho Sonu, signed a memorandum of understanding for the co-development of innovative investigational new drugs. 

The Gwangju Institute of Science and Technology is equipped with excellent basic research and technical infrastructure, has global standard research capabilities, and promotes joint research activities with outstanding researchers abroad.